Maravai LifeSciences
MRVI
223 hedge funds and large institutions have $902M invested in Maravai LifeSciences in 2023 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 81 increasing their positions, 64 reducing their positions, and 31 closing their positions.
77% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 31
27% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 64
9% more funds holding
Funds holding: 204 → 223 (+19)
1.95% more ownership
Funds ownership: 102.27% → 104.22% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
33% less capital invested
Capital invested by funds: $1.35B → $902M (-$446M)
50% less call options, than puts
Call options by funds: $1.64M | Put options by funds: $3.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1WCM
12 West Capital Management
New York
|
+$33.2M |
| 2 |
Morgan Stanley
New York
|
+$27.9M |
| 3 |
PE
Point72 Europe
London,
United Kingdom
|
+$16.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$12.2M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$74.5M |
| 2 |
Jennison Associates
New York
|
-$25.5M |
| 3 |
Holocene Advisors
New York
|
-$21.5M |
| 4 |
ClearBridge Investments
New York
|
-$14.9M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$13.8M |
MRVI Hedge Fund Activity: Q4 2023 in Review
223 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q4 2023, worth a combined $902M — down 33% from $1.35B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new MRVI positions and 31 closed out — a net gain of 24 holders — while 81 added to existing stakes and 64 trimmed.
The largest buyer was 12 West Capital Management, adding an estimated $33.2M. The largest seller was Thrivent Financial for Lutherans, cutting an estimated $74.5M.
- 223 institutional investors held Maravai LifeSciences (MRVI) as of Q4 2023, up from 204 in Q3 2023.
- Funds reported $902M of Maravai LifeSciences stock for Q4 2023, down 33% quarter-over-quarter.
- 55 funds opened new Maravai LifeSciences positions in Q4 2023 and 31 closed out, a net change of +24 holders.
- The largest Maravai LifeSciences buyer in Q4 2023 was 12 West Capital Management, an estimated $33.2M added.
- The largest Maravai LifeSciences seller in Q4 2023 was Thrivent Financial for Lutherans, an estimated $74.5M sold.
Based on aggregated 13F filings for Q4 2023.